IX. DIAGNOSTIEK EN BEHANDELING VAN HET GEMETASTASEERDE MAMMACARCINOOM

 

Op afstand gemetastaseerd mammacarcinoom moet worden beschouwd als een niet curabele ziekte. De mediane overleving na vaststelling van de metastasering is 1,5-2 jaar.1,2 Er is echter een grote heterogeniciteit in overleving; de marge kan variŽren van enkele maanden tot vele jaren.1-4 De belangrijkste doelstelling bij de behandeling van het gemetastaseerde mammacarcinoom is het handhaven of verbeteren van de kwaliteit van leven door het bestrijden van klachten.

 

 

 

1. Diagnostiek

Metastasering komt bij 75% van de patiŽnten aan het licht naar aanleiding van klachten.5 De diagnostiek is gericht op de aard van de klachten van de patiŽnte en op de bevindingen bij lichamelijk onderzoek.

 



2. Behandeling

 


 

 


 

Referenties

1.†††† Ellis MJ, Hayes DF, Lippman ME. Treatment of metastatic breast cancer. In: Diseases of the breast, eds Harris J et al. Lippincott, Williams and Wilkins, Philadelphia, 2nd Edition, 2000; 749-97.

2.†††† Hayes DF, Henderson IC, Shapiro CL. Treatment of metastatic breast cancer: present and future prospects. Semin Oncol 1995; 22: 5-19.

3.†††† Greenberg P, Hortobagyi G, Smith T, Ziegler L, Frye K, Buzdar A. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14: 2197-205.

4.†††† Falkson G, Gelman RS, Leone L, Falkson CL. Survival of premenopausal women with metastatic breast cancer. Long term follow up of Eastern Cooperative group and Cancer Leukemia Group B studies. Cancer 1990; 66: 1621-9.

5.†††† Rutgers EJTh, van Slooten EA, Kluck HH. Follow-up after treatment of primary breast cancer. Br J Surg 1989; 76: 187-90.

6.†††† Wilkins E, Head J, Burke J. Pulmonary resection for metastatic neoplasms in the lung. Experience at the Massachusetts general hospital. Am J Surg 1978; 135: 480-3.

7.†††† Layer G, Steudel A, Schuller H, van Kaick G, Grunwald F, Reiser M et al. MRI to detect bone marrow metastases in the initial staging of small cell lung carcinoma and breast carcinoma. Cancer 1999; 85: 1004-9.

8.†††† Nishimura R, Nagao K, Miyayama H, Yasunaga T, Asao C, Matsuda Y et al. Diagnostic problems of evaluating vertebral metastasis from breast cancer with a higher degree of malignancy. Cancer 1999; 85: 1782-8.

9.†††† Sheafor DH, Frederick MG, Paulson EK, Keogan MT, DeLong DM, Nelson RC. Comparison of unenhanced, hepatic arterial-dominant, and portal venous- dominant phase helical CT for the detection of liver metastases in women with breast carcinoma. AJR 1999; 172: 961-8.

10.Frederick MG, Paulson EK, Nelson RC. Helical CT for detecting focal liver lesions in patients with breast carcinoma: comparison of noncontrast phase, hepatic arterial phase, and portal venous phase. J Comput Assist Tomogr 1997; 21: 229-35.

11.Klijn JGM, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R on behalf of the Combined Hormone Agents Trialistsí Group. Combined tamoxifen and LHRH-agonist versus LHRH-agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomised trials. J Clin Oncol 2001; 19: 343-53.

12.Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomised trial involving 31510 women. J Clin Oncol 1998; 16: 3439-60.

13.Major PP, Lipton A, Berenson J, Hortobagyi G. Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer 2000; 88: 6-14

14.Hortobagyi GN, Theriault RL, Lipton A, Proter L, Blayney D, Sinoff C et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998; 16: 2038-44.

15.Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled tial. J Clin Oncol 1999; 17: 846-54.

16.Yarnold JR, on behalf of the bone pain trial working party. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow up. Radiother Oncol 1999; 52: 111-21.

17.Steenland E, Leer J, Houwelingen H van, Post WJ, van den Hout WB, Kievit J et al. The effect of a single fraction compared to multiple fractions on painful metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol 1999; 52: 101-9.

18.Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, Davis LW et al. The palliation of brain metastases. Final results of the first two studies by the Radiation Therapy Oncology Group. Int J Oncol Biol Phys 1980; 6: 1-9.

19.Maranzano E, Latini P, Checcaglini F, Perrucci E, Aristei C, Panizza BM et al. Radiation therapy of spinal cord compression caused by breast cancer:report of a prospective trial. Int J Radiat Oncol Biol Phys 1992; 24: 301-6.

20.Hill ME, Richards MA, Gregory WM, Smith P, Rubens RD. Spinal cord compression in breast cancer: a review of 70 cases. Br J Cancer 1993; 68: 969-73.